Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AB Science SA

Almirall, S.A.

Archer Pharmaceuticals, Inc.

Asana BioSciences, LLC

Celgene Corporation

F. Hoffmann-La Roche Ltd.

Genosco

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

Levolta Pharmaceuticals, Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Oscotec Inc.

Portola Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

Taiho Pharmaceutical Co., Ltd.

TopiVert Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) Overview 10

Therapeutics Development 11

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Products under Development by Stage of Development 11

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Products under Development by Therapy Area 12

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Products under Development by Indication 13

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Products under Development by Companies 17

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Products under Development by Universities/Institutes 22

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Companies Involved in Therapeutics Development 29

AB Science SA 29

Almirall, S.A. 30

Archer Pharmaceuticals, Inc. 31

Asana BioSciences, LLC 32

Celgene Corporation 33

F. Hoffmann-La Roche Ltd. 34

Genosco 35

Gilead Sciences, Inc. 36

GlaxoSmithKline Plc 37

Hutchison MediPharma Limited 38

Levolta Pharmaceuticals, Inc. 39

Merck KGaA 40

Millennium Pharmaceuticals Inc 41

Oscotec Inc. 42

Portola Pharmaceuticals, Inc. 43

Rigel Pharmaceuticals, Inc. 44

Taiho Pharmaceutical Co., Ltd. 45

TopiVert Ltd 46

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Drug Profiles 47

AB-8779 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ASN-002 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

C-13 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

CC-509 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

cerdulatinib - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

entospletinib - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

fostamatinib disodium - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

GS-9876 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

GSK-2646264 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

HMPL-523 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

LAS-189386 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

nilvadipine - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

PRT-060318 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

PRT-2761 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

R-348 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

RO-9021 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

SKIO-592 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

SKIO-703 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

SKIO-703 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecule to Inhibit SYK for Inflammation - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecules to Inhibit Spleen Tyrosine Kinase for Immunology and Oncology - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

TAK-659 - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

TAS-5567 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

TOP-1210 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

TOP-1630 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Dormant Projects 85

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Discontinued Products 90

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC

2.7.10.2) - Featured News & Press Releases 91

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 91

May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease 92

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 92

Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 93

Mar 18, 2016: Asana BioSciences, to Provide Update on ASN002, a Novel SYK/JAK Inhibitor, at the 14th International Congress on Targeted Anticancer Therapies 93

Feb 25, 2016: Rigel Initiates Phase II Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia 94

Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 94

Jan 15, 2016: Initiation of HMPL-523 Phase I clinical trial in haematological cancer in Australia 95

Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 95

Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 96

Nov 30, 2015: Asana to Present First Clinical Data of ASN002, a Novel SYK/JAK Inhibitor, at American Society of Hematology Annual Meeting 97

Oct 30, 2015: Completion of Phase I clinical trial of novel Syk Inhibitor HMPL-523 for autoimmune diseases in healthy volunteers 97

Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 98

May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 98

May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting 100

Appendix 102

Methodology 102

Coverage 102

Secondary Research 102

Primary Research 102

Expert Panel Validation 102

Contact Us 102

Disclaimer 103

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Products under Development by Companies, H2 2016 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Products under Investigation by Universities/Institutes, H2 2016 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by AB Science SA, H2 2016 29

Pipeline by Almirall, S.A., H2 2016 30

Pipeline by Archer Pharmaceuticals, Inc., H2 2016 31

Pipeline by Asana BioSciences, LLC, H2 2016 32

Pipeline by Celgene Corporation, H2 2016 33

Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 34

Pipeline by Genosco, H2 2016 35

Pipeline by Gilead Sciences, Inc., H2 2016 36

Pipeline by GlaxoSmithKline Plc, H2 2016 37

Pipeline by Hutchison MediPharma Limited, H2 2016 38

Pipeline by Levolta Pharmaceuticals, Inc., H2 2016 39

Pipeline by Merck KGaA, H2 2016 40

Pipeline by Millennium Pharmaceuticals Inc, H2 2016 41

Pipeline by Oscotec Inc., H2 2016 42

Pipeline by Portola Pharmaceuticals, Inc., H2 2016 43

Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 44

Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 45

Pipeline by TopiVert Ltd, H2 2016 46

Dormant Projects, H2 2016 85

Dormant Projects (Contd..1), H2 2016 86

Dormant Projects (Contd..2), H2 2016 87

Dormant Projects (Contd..3), H2 2016 88

Dormant Projects (Contd..4), H2 2016 89

Discontinued Products, H2 2016 90

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports